Digital surgery company Caresyntax recently closed a $100 million Series C round led by PFM Health Sciences.
The investment follows a year in which the company said it saw 250% growth in new contract value and supported more than 30,000 surgeons.
Caresyntax’s digital surgery platform uses proprietary software and artificial intelligence (AI) to analyze large volumes of real-world data in and around the operating room (OR) to deliver information that can be used immediately by the care team and longer-term by surgeons and others to assess and improve care. Caresyntax also offers virtual, real-time access to outside experts, such as medical school instructors or medical device representatives, through its digital platform.
“Operating rooms need to perform as effectively and efficiently as possible, and this is especially true now to make up for the surgical backlog driven by the pandemic,” said Caresyntax founder and CEO Dennis Kogan said in a news release. “With better technology to safely automate surgical pathways while generating decision-grade real-world evidence, we will improve health care decision-making, mitigate surgical risks and advance high-value medical technology.”
Boston-based Caresyntax said the latest funding round will help it accelerate expansion in key markets, further research and development of its AI analytics, build out its platforms and expand its employee base.